$node = stdClass Object (
[nid] => [12202]
[vid] => [12280]
[type] => [what_new]
[status] => [1]
[created] => [1225978929]
[changed] => [1249662625]
[comment] => [2]
[promote] => [0]
[sticky] => [0]
[revision_timestamp] => [1249662625]
[title] => [Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID)]
[body] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-RAID/</div></div></div><div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>The Type 1 Diabetes - Rapid Access to Intervention Development (<a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a>) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.</p>
<p>Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.</p>
<p>T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program <a href="http://dtp.nci.nih.gov/docs/raid/raid_index.html">(NCI DTP)</a>. The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. <b>T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.</b></p>
</div></div></div>]
[log] => []
[format] => [0]
[uid] => [5]
[name] => [kristin.abraham]
[picture] => []
[data] => [a:0:{}]
[path] => [type-1-diabetes-rapid-access-invervention-development-t1d-raid]
[nodewords] => []
[last_comment_timestamp] => [1225978929]
[last_comment_name] => []
[comment_count] => [0]
[taxonomy] => array (
[2283] => stdClass (
[0] => [**Recursion Detected**]
)
)
[files] => []
[field_body] => array (
[0] => array (
[value] => [<p>The Type 1 Diabetes - Rapid Access to Intervention Development (<a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a>) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.</p><p>Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.</p><p>T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program <a href="http://dtp.nci.nih.gov/docs/raid/raid_index.html">(NCI DTP)</a>. The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. <b>T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.</b></p>]
[format] => [1]
[view] => [<p>The Type 1 Diabetes - Rapid Access to Intervention Development (<a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a>) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.</p>
<p>Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.</p>
<p>T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program <a href="http://dtp.nci.nih.gov/docs/raid/raid_index.html">(NCI DTP)</a>. The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. <b>T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.</b></p>
]
)
)
[field_content_weight] => array (
[0] => array (
[value] => [-1]
)
)
[field_exrternal_link_0] => array (
[0] => array (
[value] => [http://www.t1diabetes.nih.gov/T1D-RAID/]
[view] => [http://www.t1diabetes.nih.gov/T1D-RAID/]
)
)
[page_title] => []
[readmore] => []
[content] => array (
[field_exrternal_link_0] => array (
[#access] => [1]
[#value] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-RAID/</div></div></div>]
[#weight] => [0]
[#printed] => [1]
)
[field_content_weight] => array (
[#weight] => [0]
[#value] => []
[#access] => []
)
[field_body] => array (
[#access] => [1]
[#value] => [<div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>The Type 1 Diabetes - Rapid Access to Intervention Development (<a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a>) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.</p>
<p>Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.</p>
<p>T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program <a href="http://dtp.nci.nih.gov/docs/raid/raid_index.html">(NCI DTP)</a>. The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. <b>T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.</b></p>
</div></div></div>]
[#weight] => [0]
[#printed] => [1]
)
[body] => array (
[#weight] => [0]
[#value] => []
[#printed] => [1]
)
[#children] => [<div class="field field-type-text field-field-exrternal-link-0"><div class="field-items"><div class="field-item">http://www.t1diabetes.nih.gov/T1D-RAID/</div></div></div><div class="field field-type-text field-field-body"><div class="field-items"><div class="field-item"><p>The Type 1 Diabetes - Rapid Access to Intervention Development (<a href="http://www.t1diabetes.nih.gov/T1D-RAID/">T1D-RAID</a>) program is designed to assist translation to the clinic of novel therapeutic interventions for type 1 diabetes and its complications. These potential interventions can be either synthetic, natural product, or biologic. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials.</p>
<p>Requests are accepted twice yearly, on November 1 and April 1. The requests are reviewed by a panel of extramural experts within two to three months of receipt. Review criteria include strength of the scientific hypothesis, scientific novelty, and cost/benefit considerations afforded by the proposal.</p>
<p>T1D-RAID is not a grant mechanism. Approved requests to T1D-RAID gain access to the drug development contract resources of the National Cancer Institute's Developmental Therapeutics Program <a href="http://dtp.nci.nih.gov/docs/raid/raid_index.html">(NCI DTP)</a>. The output of the use of these resources is provided to the originating investigator, and may include GMP synthesized material, formulation research, pharmacological methods, or IND-directed toxicology, for support of an investigator-held IND application and clinical trials. <b>T1D-RAID does not sponsor clinical trials; it sponsors the work needed to get ready to do clinical trials.</b></p>
</div></div></div>]
[#printed] => [1]
)
[links] => array (
[comment_forbidden] => array (
[title] => [<a href="/user/login?destination=comment/reply/12202%2523comment-form">Login</a> to post comments]
[html] => [1]
)
)
);
